Skip to Content

Prevymis (letermovir) Disease Interactions

There are 2 disease interactions with Prevymis (letermovir):


Letermovir (applies to Prevymis) hepatic dysfunction

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of letermovir is not recommended for patients with severe (Child-Pugh Class C) hepatic impairment. No dosage adjustment of letermovir is required for patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.


Letermovir (applies to Prevymis) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Hydroxypropyl betadex present in the intravenous letermovir formulation is mainly eliminated by glomerular filtration. Decreased elimination of hydroxypropyl betadex has been reported in the literature in patients with severe renal impairment. Closely monitor serum creatinine levels in patients with CrCl less than 50 mL/min using letermovir injection because accumulation of the intravenous vehicle, hydroxypropyl betadex, could occur. In patients with CrCl greater than 10 mL/min, no dosage adjustment of letermovir is required based on renal impairment. The safety of letermovir in patients with end-stage renal disease (CrCl less than 10 mL/min), including patients on dialysis, is unknown.

Prevymis (letermovir) drug interactions

There are 358 drug interactions with Prevymis (letermovir)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.